{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-031715","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.035498+00:00","generated_at":"2026-05-15T09:48:05.736184+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02","bullets":["Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.","FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.","FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.","cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.","Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-031715","json":"https://secwatch.observer/filing/0001104659-26-031715.json","markdown":"https://secwatch.observer/filing/0001104659-26-031715.md","text":"https://secwatch.observer/filing/0001104659-26-031715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/0001104659-26-031715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/tm269341d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:48:05.736184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}